First, we evaluated SM1 melanoma tumor cells collected from mice treated with vehicle control, anti-PD-1 antibody, NextA, or a combination of both agents for expression of PD-L1 and other immune-regulatory surface markers by flow cytometry. This evidence concerns the gene PDCD1 and melanoma.